| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 160 | 170 | 210 | 190 | 350 |
| Sales Growth | -5.88% | -19.05% | +10.53% | -45.71% | -31.37% |
| Net Income | 1,880 | -320 | -310 | -400 | -380 |
| Net Income Growth | +687.50% | -3.23% | +22.50% | -5.26% | -18.75% |
American Bio Medica Corp (ABMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
American Bio Medica develops, manufactures and markets biomedical technologies and products intended for the immediate, onsite screening for drugs of abuse. Their products offer health care, law enforcement, government, industrial safety and educational professionals, self-contained, one-step screening devices capable of identifying illicit drug use within minutes.
Fiscal Year End Date: 12/31